Teleflex Incorporated has today announced key milestones in the release of two new catheters, including the US Food and Drug Administration (FDA) 510(k) clearance of the Triumph catheter, and the first clinical use of GuideLiner Coast catheter.
The Triumph catheter is the latest addition to the Teleflex family of catheters, which includes the GuideLiner V3, TrapLiner, and Turnpike catheters. Designed in collaboration with Bill Nicholson (Emory Healthcare, Atlanta, USA) the Triumph catheter features a design with six wire exit ports for precise wire advancement and clear visualisation, the company said in a press release.
“In complex cases, the ability to better navigate tortuous anatomy has long been a challenge,” said Nicholson. “The Triumph catheter’s nitinol ports and cage bring navigation and control to a new level, and I am excited that Teleflex will enable interventional cardiologists to readily access this important technology.”
The GuideLiner Coast catheter adds a hydrophilic option to Teleflex’s guide extension portfolio—anchored by the flagship GuideLiner V3 catheter—enabling physicians to select the level of deliverability and backup support needed for specific cases. Earlier this year, the GuideLiner Coast Catheter was first used in a clinical procedure at the UW Medicine Heart Institute (Seattle, USA).
The GuideLiner Coast catheter is currently in a limited market release phase, with full market release anticipated later this year.